Reviva Pharmaceuticals announced that enrollment is complete in the pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia, with 402 patients enrolled at multiple sites in the United States (~60%), Europe (~10%), and Asia (~30%). Topline data for Phase 3 RECOVER study expected in October 2023. Completion of 1-year open-label extension clinical study expected in Q3 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVPH:
- Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
- Reviva Pharmaceuticals reports Q2 EPS (55c), consensus (28c)
- Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- RVPH Upcoming Earnings Report: What to Expect?
- Reviva Pharmaceuticals to be Added to Russell Microcap® Index